[go: up one dir, main page]

HRP20130242T1 - Smrzavanjem osušene formulacije fsh/lh - Google Patents

Smrzavanjem osušene formulacije fsh/lh Download PDF

Info

Publication number
HRP20130242T1
HRP20130242T1 HRP20130242TT HRP20130242T HRP20130242T1 HR P20130242 T1 HRP20130242 T1 HR P20130242T1 HR P20130242T T HRP20130242T T HR P20130242TT HR P20130242 T HRP20130242 T HR P20130242T HR P20130242 T1 HRP20130242 T1 HR P20130242T1
Authority
HR
Croatia
Prior art keywords
freeze
formulation according
dried formulation
fsh
follicle
Prior art date
Application number
HRP20130242TT
Other languages
English (en)
Inventor
Fabrizio Samaritani
Piergiorgio Donati
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33522382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130242(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of HRP20130242T1 publication Critical patent/HRP20130242T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Claims (21)

1. Smrzavanjem osušena formulacija naznačena time da sadrži folikulostimulirajući hormon (FSH) ili njegovu varijantu kao i luteinizirajući hormon (LH) ili njegovu varijantu, surfaktant koji je odabran od polisorbata uključujući Tween 20 (polioksietilen (20) sorbitan monolaurat), Tween 40 (polioksietilen (20) sorbitan monopalmitat), Tween 80 (polioksietilen (20) sorbitan monooleat), antioksidans koji je metionin, fosfatni pufera i stabilizator, te tonično sredstvo koje je odabrano iz skupine koja sadrži monosaharide, disaharide i šećerne alkohole.
2. Smrzavanjem osušena formulacija prema zahtjevu 1, naznačena time da surfaktant je Tween 20.
3. Smrzavanjem osušena formulacija prema bilo kojem od zahtjeva 1 ili 2, naznačena time da folikulostimulirajući hormon je ljudski folikulostimulirajući hormon i/ili luteinizirajući hormon (LH) je ljudski luteinizirajući hormon (LH).
4. Smrzavanjem osušena formulacija prema zahtjevu 3, naznačena time da folikulostimulirajući hormon je ljudski urinarni folikulostimulirajući hormon i/ili luteinizirajući hormon (LH) je ljudski urinarni luteinizirajući hormon (LH).
5. Smrzavanjem osušena formulacija prema bilo kojem od zahtjeva 1 do 3, naznačena time da folikulostimulirajući hormon je ljudski rekombinantni folikulostimulirajući hormon i/ili luteinizirajući hormon (LH) je ljudski rekombinantni luteinizirajući hormon (LH).
6. Smrzavanjem osušena formulacija prema bilo kojem od prethodnih zahtjeva; naznačena time da je folikulostimulirajući hormon (FSH) prisutan u koncentraciji (tež./tež.) od ili oko 0.1 do 10 μg/mg ukupne formulacije.
7. Smrzavanjem osušena formulacija prema zahtjevu 6, naznačena time da je folikulostimulirajući hormon (FSH) prisutan u koncentraciji od ili oko 0.3 do 5 μg/mg ukupne formulacije.
8. Smrzavanjem osušena formulacija prema zahtjevu 7, naznačena time da je folikulostimulirajući hormon (FSH) prisutan u koncentraciji od ili oko 0.37 do 2 μg/mg ukupne formulacije.
9. Smrzavanjem osušena formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da je luteinizirajući hormon (LH) prisutan u koncentraciji od ili oko 0.1 do 3 μg/mg ukupne formulacije.
10. Smrzavanjem osušena formulacija prema zahtjevu 9, naznačena time da je luteinizirajući hormon (LH) prisutan u koncentraciji od ili oko 0.1 do 1 μg/mg ukupne formulacije.
11. Smrzavanjem osušena formulacija prema zahtjevu 10, naznačena time da je luteinizirajući hormon (LH) prisutan u koncentraciji od ili oko 0.1 do 0.6 μg/mg ukupne formulacije.
12. Smrzavanjem osušena formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da je omjer FSH prema LH u rasponu od ili oko 6:1 do točno ili oko 1:6.
13. Smrzavanjem osušena formulacija prema zahtjevu 12, naznačena time da je omjer FSH prema LH u rasponu od ili oko 4:1 do točno ili oko 1:2.
14. Smrzavanjem osušena formulacija prema zahtjevu 13, naznačena time da je omjer FSH prema LH u rasponu od ili oko 3:1 do točno ili oko 1:1.
15. Smrzavanjem osušena formulacija prema zahtjevu 14, naznačena time da je omjer FSH prema LH u rasponu od ili oko 2:1 i 1:1.
16. Smrzavanjem osušena formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da je stabilizator i tonično sredstvo, sukroza.
17. Smrzavanjem osušena formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da se sastoji od slijedećih sastojaka: rFSH, rLH, Tween 20, sukroze, metionina, fosfatnog pufera.
18. Smrzavanjem osušena formulacija prema bilo kojem od zahtjeva 1 do 17, naznačena time da relativne težinske količine komponenti iznose 12.0 μg rekombinantnog FSH, 3.7 μg rekombinantnog LH, 30.0 mg sukroze, 0.45 mg NaH2PO4 H2O, 1.11 mg NaH2PO4 2H2O, 0.05 mg Tween 20 i 0.1 mg L-metionina.
19. Pripravak naznačen time da sadrži prvi spremnik ispunjen sa smrzavanjem osušenom formulacijom prema bilo kojem zahtjevu od 1 do 18 i drugi spremnik koji sadrži otapalo za rekonstituciju.
20. Pripravak prema zahtjevu 19, naznačen time da drugi spremnik sadrži vodu za rekonstituciju.
21. Postupak za proizvodnju smrzavanjem osušene formulacije prema bilo kojem zahtjevu od 1 do 18, naznačen time da sadrži korak formiranja smjese koja se sastoji od FSH sa LH, i od surfaktanta koji je odabran od polisorbata uključujući Tween 20 (polioksietilen (20) sorbitan monolaurat), Tween 40 (polioksietilen (20) sorbitan monopalmitat), Tween 80 (polioksietilen (20) sorbitan monooleat), antioksidansa koji je metionin, fosfatnog pufera i stabilizatora, te toničnog sredstva koje je odabrano iz skupine koja sadrži monosaharide, disaharide i šećerne alkohole, te podvrgavanja dobivene smjese liofilizaciji.
HRP20130242TT 2003-06-20 2004-06-16 Smrzavanjem osušene formulacije fsh/lh HRP20130242T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101830 2003-06-20
PCT/EP2004/051138 WO2004112826A1 (en) 2003-06-20 2004-06-16 Freeze-dried fsh / lh formulations

Publications (1)

Publication Number Publication Date
HRP20130242T1 true HRP20130242T1 (hr) 2013-04-30

Family

ID=33522382

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130242TT HRP20130242T1 (hr) 2003-06-20 2004-06-16 Smrzavanjem osušene formulacije fsh/lh

Country Status (15)

Country Link
US (1) US7740884B2 (hr)
EP (1) EP1638595B1 (hr)
JP (1) JP4871124B2 (hr)
AU (1) AU2004248931B2 (hr)
CA (1) CA2526099C (hr)
CY (1) CY1114121T1 (hr)
DK (1) DK1638595T3 (hr)
ES (1) ES2414705T3 (hr)
HR (1) HRP20130242T1 (hr)
IL (1) IL172353A (hr)
NO (1) NO330210B1 (hr)
PL (1) PL1638595T3 (hr)
PT (1) PT1638595E (hr)
SI (1) SI1638595T1 (hr)
WO (1) WO2004112826A1 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
KR101483165B1 (ko) * 2009-12-22 2015-01-15 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 인간폐경성선자극호르몬의 조성물
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
US11376220B2 (en) 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals
CN108096199B (zh) * 2018-01-15 2020-08-25 常州市第四制药厂有限公司 一种注射用奥美拉唑钠及制备方法
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
AR117743A1 (es) 2019-12-30 2021-08-25 Univ Nacional Del Litoral Unl MÉTODO DE OBTENCIÓN DE UNA LÍNEA CELULAR DE MAMÍFERO QUE EXPRESA UNA HORMONA GONADOTROFINA CORIÓNICA EQUINA RECOMBINANTE (reCG), LÍNEA CELULAR QUE EXPRESA reCG, MÉTODO DE PRODUCCIÓN A ESCALA DE reCG, reCG, FORMULACIONES QUE LA CONTIENEN, ÁCIDOS NUCLEICOS QUE CODIFICAN PARA reCG Y USOS

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB839300A (en) 1957-09-05 1960-06-29 Organon Labor Ltd Adrenocorticotropic hormone preparations and process for making same
FR3819M (fr) 1963-03-11 1966-01-10 Serono Ist Farm Nouvelle hormone hypophysaire a activité différenciée.
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5639639A (en) * 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4589402A (en) * 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4780451B1 (en) 1987-01-23 1995-04-04 Asua International Inc Composition and method for producing superovulation in cattle
US5162306A (en) * 1987-01-23 1992-11-10 Donaldson Lloyd E Composition and method for producing superovulation in mammals
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
EP0318081B1 (en) 1987-11-27 1991-07-24 Akzo N.V. Stabilization of antibodies
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
DE4117078A1 (de) 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
US5508261A (en) * 1991-06-18 1996-04-16 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same
DE69231129D1 (de) 1991-06-18 2000-07-06 Univ New Jersey Med Analoga von glykoproteinhormonen mit geänderter rezeptorbindungsspezifität und aktivität und verfahren zur darstellung und verwendung derselben
IT1250075B (it) 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5356876A (en) * 1992-01-13 1994-10-18 Trinity University Methods of terminating pregnancy
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
ATE359824T1 (de) 1992-07-31 2007-05-15 Genentech Inc Wässrige formulierung enthaltend menschliches wachstumshormon
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
AU695125B2 (en) * 1993-02-02 1998-08-06 Xoma Corporation Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
DE69508985T2 (de) 1994-02-21 1999-08-19 Takeda Chemical Industries Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
ATE223221T1 (de) * 1994-12-22 2002-09-15 Ortho Pharma Corp Lösliche arzneizusammensetzungen enthaltend 2- chloro-2'-deoxyadenosine
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
TR199800811T2 (xx) 1995-11-07 1998-07-21 Genentech,Inc. NGF i�in stabilize edici form�lasyonlar.
CN1244110A (zh) * 1996-12-23 2000-02-09 诺沃挪第克公司 用于储存液体药物的环状烃聚合物药物容器
US6136784A (en) * 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US7311912B1 (en) 1997-01-10 2007-12-25 Plantbodies Corporation Epithelial tissue targeting agent
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US20010007673A1 (en) * 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
JP2001520984A (ja) 1997-10-27 2001-11-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 水難溶性薬剤の固態溶剤及び固体分散体
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP4719357B2 (ja) 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
FR2782455B3 (fr) 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
AU765584B2 (en) * 1998-09-17 2003-09-25 Eli Lilly And Company Protein formulations
IL146252A0 (en) 1999-05-07 2002-07-25 Applied Research Systems Use of gonadotrophin in induction of folliculogenesis
ATE445013T1 (de) 1999-06-30 2009-10-15 Takeda Pharmaceutical Polypeptide und deren dna
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations

Also Published As

Publication number Publication date
SI1638595T1 (sl) 2013-04-30
ES2414705T3 (es) 2013-07-22
EP1638595B1 (en) 2013-03-20
JP4871124B2 (ja) 2012-02-08
IL172353A (en) 2013-04-30
JP2009514777A (ja) 2009-04-09
US20070059252A1 (en) 2007-03-15
AU2004248931B2 (en) 2009-07-16
PL1638595T3 (pl) 2013-06-28
NO330210B1 (no) 2011-03-07
NO20060241L (no) 2006-01-17
WO2004112826A1 (en) 2004-12-29
AU2004248931A1 (en) 2004-12-29
CA2526099C (en) 2013-02-05
CY1114121T1 (el) 2016-07-27
EP1638595A1 (en) 2006-03-29
CA2526099A1 (en) 2004-12-29
PT1638595E (pt) 2013-04-26
US7740884B2 (en) 2010-06-22
DK1638595T3 (da) 2013-04-08

Similar Documents

Publication Publication Date Title
HRP20130242T1 (hr) Smrzavanjem osušene formulacije fsh/lh
EP3169313B1 (en) A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
CN101909450B (zh) 用于抗击寄生物的浇泼配制剂的溶剂系统
SI2198007T1 (en) Pharmaceutical compositions containing Clostridium difficile A and B toxoids
CN1351489A (zh) 含有植物物质的颗粒及其制备方法
US20250019421A1 (en) Pharmaceutical formulation comprising bispecific antibody against rabies virus g protein and preparation method therefor
CN102217638B (zh) 一种用于防治植物病毒病的农药组合物
WO2011027333A1 (en) Granulated anthelmintic preparations and delivery systems
TW200621310A (en) A process for preparing formulations of lypophilic active substances by spray freeze drying
HRP20240176T1 (hr) Formulacije
CN1075833C (zh) 香料小球及制备方法
CN103505723B (zh) 狂犬疫苗冻干制剂的制备方法
CN104957161A (zh) 含甲氨基阿维菌素苯甲酸盐与虱螨脲的微乳剂
CN102176899A (zh) 苯并咪唑驱虫药组合物
CN110896948A (zh) 一种含有d-柠檬烯的杀虫组合物
CN117178982A (zh) 一种马铃薯甲虫核酸干扰素液体制剂及其应用
EP3075377B1 (en) Oral compositions comprising powdered plant extracts
JP2008509161A5 (hr)
CN103040765B (zh) 含三磷酸腺苷二钠的药物组合物及其制备方法
AU2006100580B4 (en) Pesticide composition
CN104740637A (zh) 一种稳定的奥利司他口服制剂及其制备方法
WO2017129496A1 (en) Granular compositions having insecticidal activity
CN106456704A (zh) 兽药组合物和其应用
CN104800809B (zh) 姜汁足浴盐及其加工方法
KR102245041B1 (ko) 휴지기간이 없는 입욕제 제조방법